Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO
He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions.
Comments